Century Therapeutics Inc (IPSC)vsModerna Inc (MRNA)
IPSC
Century Therapeutics Inc
$1.89
+2.16%
HEALTHCARE · Cap: $351.29M
MRNA
Moderna Inc
$182.56
+5.56%
HEALTHCARE · Cap: $69.04B
Smart Verdict
WallStSmart Research — data-driven comparison
IPSC leads profitability with a 0.0% profit margin vs -141.4%. IPSC earns a higher WallStSmart Score of 34/100 (F).
IPSC
Avoid34
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IPSC.
Margin of Safety
+69.9%
Fair Value
$134.69
Current Price
$182.56
$47.87 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Trading at 10.8x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : IPSC
The strongest argument for IPSC centers on Price/Book, Debt/Equity.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : IPSC
The primary concerns for IPSC are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
IPSC profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
IPSC carries more volatility with a beta of 1.60 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
IPSC generates stronger free cash flow (-21M), providing more financial flexibility.
Bottom Line
IPSC scores higher overall (34/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Century Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Century Therapeutics Inc. (Ticker: IPSC) is a leading biotechnology company specializing in allogenic cell therapy, with a transformative approach to cancer treatment. Leveraging its pioneering induced pluripotent stem cell (iPSC) technology, Century is committed to developing innovative off-the-shelf therapeutics designed to improve patient outcomes and expand accessibility to care. With a diverse array of clinical-stage assets and strategic collaborations that enhance its market position, Century Therapeutics presents compelling investment opportunities in the burgeoning cell therapy landscape, positioning itself for significant growth within the biotech industry.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?